Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
Clinical trial NCT05927142 · RECRUITING
Trial details
- NCT number
- NCT05927142
- Sponsor
- Joachim Aerts, MD PhD
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-09
- Primary completion
- 2026-04-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.